FMT with immunotherapy and chemotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or recurrent non-small cell lung cancer that cannot be surgically removed and is not suitable for intensive chemo-radiation.
- You must not have had any prior systemic cancer treatment (like chemotherapy or immunotherapy) for your lung cancer, and your cancer must not have a treatable driver gene mutation.
- The PD-L1 level on your cancer cells must be less than 50%.
- You should be between 18 and 80 years old, have a good performance status (ECOG 0-1), and have at least one tumor that can be measured on a CT or MRI scan.
- Your blood counts, liver and kidney function must meet certain minimum levels, and you must not have serious heart conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a fecal microbiota transplant (a stool transplant from a healthy donor or someone who responded well to immunotherapy) together with the immunotherapy drug tislelizumab can help people with advanced or metastatic non-small cell lung cancer (NSCLC). It's for patients whose cancer grew after prior immunotherapy.
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
This trial tests if a fecal transplant from immunotherapy responders can help treat stage II-III non-small cell lung cancer patients who haven't had treatment yet.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of fecal microbiota transplant (FMT), an immunotherapy drug (QL1706), a targeted therapy (bevacizumab), and chemotherapy (XELOX) as a first treatment for advanced colon cancer that has spread to the liver. The goal is to see if this mix can help shrink tumors and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.